Flare Therapeutics is a biotechnology company focused on developing small molecule medicines by exploring the biology of transcription factors. The company utilizes insights from its scientific founders to identify "switch sites," which are druggable regions that play a crucial role in regulating transcription factors and addressing disease-related mutations. Flare's innovative drug discovery efforts have led to a promising pipeline of drug programs targeting well-validated transcription factors, with an initial emphasis on precision oncology. The company's platform also holds potential for applications in neurology, rare genetic disorders, immunology, and inflammation, aiming to transform treatment approaches for various diseases.
Terremoto Biosciences is a biotechnology company focused on drug delivery and discovery, specializing in small-molecule medicines. The company utilizes lysine-based covalency to develop optimized therapies with enhanced clinical profiles and superior therapeutic benefits. Terremoto's innovative platform aims to improve existing medicines and create new treatments for serious diseases, contributing to advancements in the healthcare sector.
MoMa Therapeutics, Inc. discovers precision medicines by targeting the molecular machines that underlie human disease. MoMa Therapeutics, Inc. was formerly known as ATPases NewCo, Inc. and changed its name to MoMa Therapeutics, Inc. in March 2020. The company was founded in 2019 and is based in Cambridge, Massachusetts.
Celsius Therapeutics is a biotechnology company focused on developing innovative medicines to treat complex diseases, including autoimmunity and cancer. Founded in 2017 and based in Cambridge, Massachusetts, the company leverages advanced techniques such as single-cell genomic analysis and machine learning to gain insights into the cellular ecosystems of diseases. By systematically applying single-cell sequencing and analyzing extensive datasets with sophisticated algorithms, Celsius Therapeutics aims to discover critical biomarkers and precision therapies that enhance patient care and enable clinicians to identify genes that play a causal role in various conditions.
Operator of a biotechnology company intended to provide novel small molecule medicines targeting g-protein-coupled receptors. The company provides industrial-scale drug discovery using novel screening technologies and structure-based drug design, enabling medical researchers to easily find patients' treatments for a wide range of diseases.
Ambys Medicines, Inc. is a biotechnology company based in Redwood City, California, founded in 2016. The company focuses on discovering and developing innovative therapies for severe liver diseases. Its approach includes gene therapy, drug therapy, and cell therapy, aiming to restore liver function, halt the progression of liver disease, and address the serious complications associated with liver failure. Through its research and development efforts, Ambys Medicines seeks to significantly improve the quality of life for individuals affected by liver-related health issues.
Cedilla Therapeutics, Inc. is focused on developing targeted small-molecule medicines aimed at treating cancer and other diseases resulting from protein dysregulation. The company leverages unique insights into protein stability to create innovative therapeutic approaches, including direct ligand-induced degradation, disruption of protein-protein interactions, and the identification of upstream regulators that influence protein stability. Cedilla’s technology allows for the mapping of protein susceptibility to enhance endogenous degradation pathways, facilitating the transition from stable to susceptible protein states. Founded in 2018 and headquartered in Cambridge, Massachusetts, Cedilla Therapeutics aims to broaden the applicability of its therapies beyond oncology, addressing a range of conditions associated with protein dysregulation.
Asher Biotherapeutics, Inc. is a biotechnology company focused on developing immunotherapy drugs for cancer treatment. Founded in 2019 and headquartered in South San Francisco, California, the company aims to create innovative therapeutic solutions to improve patient outcomes in oncology. Asher Bio leverages advanced technologies and research to enhance the effectiveness of immune-based therapies, positioning itself as a key player in the evolving field of cancer treatment.
Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with progressive multiple sclerosis (MS) and other severe autoimmune and inflammatory diseases.
Flare Therapeutics is a biotechnology company focused on developing small molecule medicines by exploring the biology of transcription factors. The company utilizes insights from its scientific founders to identify "switch sites," which are druggable regions that play a crucial role in regulating transcription factors and addressing disease-related mutations. Flare's innovative drug discovery efforts have led to a promising pipeline of drug programs targeting well-validated transcription factors, with an initial emphasis on precision oncology. The company's platform also holds potential for applications in neurology, rare genetic disorders, immunology, and inflammation, aiming to transform treatment approaches for various diseases.
Asher Biotherapeutics, Inc. is a biotechnology company focused on developing immunotherapy drugs for cancer treatment. Founded in 2019 and headquartered in South San Francisco, California, the company aims to create innovative therapeutic solutions to improve patient outcomes in oncology. Asher Bio leverages advanced technologies and research to enhance the effectiveness of immune-based therapies, positioning itself as a key player in the evolving field of cancer treatment.
Insitro, Inc. is a data-driven drug discovery and development company based in South San Francisco, California, founded in 2018. The company utilizes machine learning and high-throughput biology to transform the traditional processes of drug discovery and delivery. By generating extensive functional genomic datasets and aligning them with patient data through innovative machine learning techniques, Insitro builds predictive models that aim to address critical challenges in pharmaceutical research and development. These models facilitate accelerated target selection and the design of effective therapeutics, ultimately enhancing the efficiency of drug development and informing clinical strategies. The focus of Insitro's work includes the treatment of nonalcoholic steatohepatitis (NASH), showcasing its commitment to addressing significant health issues through advanced technology.
Faze Medicines is a biotechnology company established in 2020 and based in Cambridge, Massachusetts. The company focuses on developing small molecule drugs targeting the underlying drivers of disease pathology, particularly for conditions such as amyotrophic lateral sclerosis (ALS) and myotonic dystrophy type 1 (DM1). Faze Medicines leverages innovative research on biomolecular condensates to create potential therapeutic breakthroughs. Through advanced screening and proteomics techniques, the company aims to pioneer new treatments for various diseases, including frontotemporal dementia (FTD) and DM1, thereby addressing significant unmet medical needs.
Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing therapies aimed at protecting, repairing, and restoring hearing. The company focuses on a range of hearing disorders, including those related to cancer treatments, cystic fibrosis, noise exposure, age-related and genetic hearing loss, as well as tinnitus. It utilizes advanced techniques such as single-cell genomics, bioinformatics, and precision gene therapy technologies to enhance its understanding of inner ear pathology and to develop effective treatments. Decibel Therapeutics also offers expertise in drug delivery to the inner ear, imaging, and pharmacokinetic modeling, contributing to innovative therapeutic approaches for patients experiencing various forms of hearing loss. Founded in 2013 and based in Boston, Massachusetts, Decibel Therapeutics was previously known as Hearing, Inc. before rebranding in 2014.
Cedilla Therapeutics, Inc. is focused on developing targeted small-molecule medicines aimed at treating cancer and other diseases resulting from protein dysregulation. The company leverages unique insights into protein stability to create innovative therapeutic approaches, including direct ligand-induced degradation, disruption of protein-protein interactions, and the identification of upstream regulators that influence protein stability. Cedilla’s technology allows for the mapping of protein susceptibility to enhance endogenous degradation pathways, facilitating the transition from stable to susceptible protein states. Founded in 2018 and headquartered in Cambridge, Massachusetts, Cedilla Therapeutics aims to broaden the applicability of its therapies beyond oncology, addressing a range of conditions associated with protein dysregulation.
Casma Therapeutics is a developer of a natural cellular process of autophagy to open new target areas for drug discovery and development. The company focuses on autophagy system to improve the cellular process of clearing out unwanted proteins, organelles and invading pathogens as well as tries to arrest or reverse the progression of lysosomal storage disorders, muscle disorders, inflammatory disorders and neurodegeneration, enabling physicians to address unmet medical needs.
Thrive Earlier Detection Corp. is a healthcare company dedicated to improving cancer detection through innovative technology. It focuses on the development of CancerSEEK, a liquid biopsy test that analyzes genomic mutations in tumor DNA and protein markers in plasma to identify multiple types of cancer at their earliest stages, often before symptoms become apparent. Founded in 2018 and headquartered in Cambridge, Massachusetts, with an additional office in Baltimore, Maryland, Thrive aims to integrate early cancer detection into routine medical care. The company was previously known as Thrive Sciences Inc. and has been a subsidiary of Exact Sciences Corporation since early 2021. Thrive was launched with support from various investors, including Third Rock Ventures and Section 32, reflecting a strong commitment to advancing cancer diagnostics.
Insitro, Inc. is a data-driven drug discovery and development company based in South San Francisco, California, founded in 2018. The company utilizes machine learning and high-throughput biology to transform the traditional processes of drug discovery and delivery. By generating extensive functional genomic datasets and aligning them with patient data through innovative machine learning techniques, Insitro builds predictive models that aim to address critical challenges in pharmaceutical research and development. These models facilitate accelerated target selection and the design of effective therapeutics, ultimately enhancing the efficiency of drug development and informing clinical strategies. The focus of Insitro's work includes the treatment of nonalcoholic steatohepatitis (NASH), showcasing its commitment to addressing significant health issues through advanced technology.
MoMa Therapeutics, Inc. discovers precision medicines by targeting the molecular machines that underlie human disease. MoMa Therapeutics, Inc. was formerly known as ATPases NewCo, Inc. and changed its name to MoMa Therapeutics, Inc. in March 2020. The company was founded in 2019 and is based in Cambridge, Massachusetts.
Nurix Therapeutics is a biopharmaceutical company dedicated to the discovery and development of small molecule therapies aimed at treating cancer and immune disorders. The company focuses on innovative approaches to modulate cellular protein levels, utilizing its expertise in the ubiquitin-proteasome system. Its lead preclinical candidates include NX-2127, an orally available Bruton’s tyrosine kinase (BTK) degrader targeting relapsed or refractory B-cell malignancies, and NX-1607, a Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology applications. Nurix also offers DELigase, a discovery platform that identifies and advances novel drug candidates by targeting E3 ligases, which play a crucial role in protein regulation. Founded in 2009 and based in San Francisco, the company has established strategic collaborations with major pharmaceutical firms, enhancing its potential in the competitive biopharmaceutical landscape.
Element Science, Inc. is a medical device and digital health company focused on developing solutions for high-risk cardiovascular patients. The company's flagship product is a patch-based wearable cardioverter defibrillator that continuously monitors heart activity to protect against sudden cardiac death. This device integrates advanced data science and machine learning algorithms with strict electromechanical medical device standards, creating a proprietary digital platform that enhances patient care as individuals transition from hospital to home. Founded in 2011 and headquartered in San Francisco, California, Element Science aims to address critical health needs and reduce hospitalization rates associated with heart disease. The company was previously known as Revive Defibrillation Systems, Inc. before adopting its current name in 2014.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.
Thrive Earlier Detection Corp. is a healthcare company dedicated to improving cancer detection through innovative technology. It focuses on the development of CancerSEEK, a liquid biopsy test that analyzes genomic mutations in tumor DNA and protein markers in plasma to identify multiple types of cancer at their earliest stages, often before symptoms become apparent. Founded in 2018 and headquartered in Cambridge, Massachusetts, with an additional office in Baltimore, Maryland, Thrive aims to integrate early cancer detection into routine medical care. The company was previously known as Thrive Sciences Inc. and has been a subsidiary of Exact Sciences Corporation since early 2021. Thrive was launched with support from various investors, including Third Rock Ventures and Section 32, reflecting a strong commitment to advancing cancer diagnostics.
Insitro, Inc. is a data-driven drug discovery and development company based in South San Francisco, California, founded in 2018. The company utilizes machine learning and high-throughput biology to transform the traditional processes of drug discovery and delivery. By generating extensive functional genomic datasets and aligning them with patient data through innovative machine learning techniques, Insitro builds predictive models that aim to address critical challenges in pharmaceutical research and development. These models facilitate accelerated target selection and the design of effective therapeutics, ultimately enhancing the efficiency of drug development and informing clinical strategies. The focus of Insitro's work includes the treatment of nonalcoholic steatohepatitis (NASH), showcasing its commitment to addressing significant health issues through advanced technology.
Maze Therapeutics is a biotechnology company based in South San Francisco, California, that specializes in the development of genetic modifier therapeutics. Founded in 2017 and formerly known as Modulus Therapeutics, the company is dedicated to translating genetic insights into innovative medicines. Maze Therapeutics utilizes a comprehensive approach that integrates large-scale human genetics data, functional genomics, and various drug discovery methodologies. This approach allows the company to identify modifier genes that offer protection against diseases, enhancing the understanding of target biology and informing drug development strategies. By leveraging these insights, Maze Therapeutics aims to facilitate the creation of novel therapies that can benefit patients.
Ambys Medicines, Inc. is a biotechnology company based in Redwood City, California, founded in 2016. The company focuses on discovering and developing innovative therapies for severe liver diseases. Its approach includes gene therapy, drug therapy, and cell therapy, aiming to restore liver function, halt the progression of liver disease, and address the serious complications associated with liver failure. Through its research and development efforts, Ambys Medicines seeks to significantly improve the quality of life for individuals affected by liver-related health issues.
Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing therapies aimed at protecting, repairing, and restoring hearing. The company focuses on a range of hearing disorders, including those related to cancer treatments, cystic fibrosis, noise exposure, age-related and genetic hearing loss, as well as tinnitus. It utilizes advanced techniques such as single-cell genomics, bioinformatics, and precision gene therapy technologies to enhance its understanding of inner ear pathology and to develop effective treatments. Decibel Therapeutics also offers expertise in drug delivery to the inner ear, imaging, and pharmacokinetic modeling, contributing to innovative therapeutic approaches for patients experiencing various forms of hearing loss. Founded in 2013 and based in Boston, Massachusetts, Decibel Therapeutics was previously known as Hearing, Inc. before rebranding in 2014.
Celsius Therapeutics is a biotechnology company focused on developing innovative medicines to treat complex diseases, including autoimmunity and cancer. Founded in 2017 and based in Cambridge, Massachusetts, the company leverages advanced techniques such as single-cell genomic analysis and machine learning to gain insights into the cellular ecosystems of diseases. By systematically applying single-cell sequencing and analyzing extensive datasets with sophisticated algorithms, Celsius Therapeutics aims to discover critical biomarkers and precision therapies that enhance patient care and enable clinicians to identify genes that play a causal role in various conditions.
Casma Therapeutics is a developer of a natural cellular process of autophagy to open new target areas for drug discovery and development. The company focuses on autophagy system to improve the cellular process of clearing out unwanted proteins, organelles and invading pathogens as well as tries to arrest or reverse the progression of lysosomal storage disorders, muscle disorders, inflammatory disorders and neurodegeneration, enabling physicians to address unmet medical needs.
Insitro, Inc. is a data-driven drug discovery and development company based in South San Francisco, California, founded in 2018. The company utilizes machine learning and high-throughput biology to transform the traditional processes of drug discovery and delivery. By generating extensive functional genomic datasets and aligning them with patient data through innovative machine learning techniques, Insitro builds predictive models that aim to address critical challenges in pharmaceutical research and development. These models facilitate accelerated target selection and the design of effective therapeutics, ultimately enhancing the efficiency of drug development and informing clinical strategies. The focus of Insitro's work includes the treatment of nonalcoholic steatohepatitis (NASH), showcasing its commitment to addressing significant health issues through advanced technology.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.
Cedilla Therapeutics, Inc. is focused on developing targeted small-molecule medicines aimed at treating cancer and other diseases resulting from protein dysregulation. The company leverages unique insights into protein stability to create innovative therapeutic approaches, including direct ligand-induced degradation, disruption of protein-protein interactions, and the identification of upstream regulators that influence protein stability. Cedilla’s technology allows for the mapping of protein susceptibility to enhance endogenous degradation pathways, facilitating the transition from stable to susceptible protein states. Founded in 2018 and headquartered in Cambridge, Massachusetts, Cedilla Therapeutics aims to broaden the applicability of its therapies beyond oncology, addressing a range of conditions associated with protein dysregulation.
Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing therapeutics aimed at addressing significant unmet medical needs in cancer treatment, particularly those related to abnormal gene expression and drug resistance. The company's lead product candidates include CPI-0610, currently undergoing Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, which is in Phase Ib/II trials for metastatic castration-resistant prostate cancer alongside androgen receptor signaling inhibitors. Additionally, Constellation is developing CPI-0209, which is in the dose escalation phase of a Phase I/II clinical trial for solid tumors. Founded in 2008, the company was previously known as Epigenetix, Inc. and has established itself as a pioneer in the emerging field of epigenetics, which focuses on selective regulators of epigenetic function crucial for gene expression control.
Rheos Medicines, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, established in 2017. The company focuses on developing novel therapeutics that modulate metabolic pathways in immune cells to address immune-mediated diseases, including inflammatory bowel disease, rheumatoid arthritis, and lupus. By targeting the cellular metabolism of immune cells, Rheos aims to redirect the fate and function of specific cell types, thereby enhancing the precision of treatments for these conditions. The company combines the expertise of leading scientists in immunometabolism with clinicians experienced in immune-mediated diseases, supported by an accomplished biotech leadership team, to identify new drug targets and characterize disease biomarkers.
Relay Therapeutics is a clinical-stage precision medicines company based in Cambridge, Massachusetts, focused on transforming the drug discovery process, particularly in targeted oncology. The company employs an innovative allosteric drug-discovery platform that integrates computational techniques with experimental methods to analyze protein motion and interactions. This approach aids in the development of therapies for complex diseases, including cancer. Relay's product candidates include RLY-1971, an oral small molecule inhibitor targeting SHP2, currently undergoing Phase 1 trials for advanced solid tumors; RLY-4008, a selective inhibitor of FGFR2 for tumors with specific oncogenic alterations; and RLY-PI3K1047, which targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. Founded in 2015, Relay Therapeutics is dedicated to enhancing small molecule therapeutic discovery through its advanced platform and targeted treatment strategies.
PanOptica, Inc. is a biopharmaceutical company focused on developing innovative topical eye drops for the treatment of sight-threatening eye diseases associated with abnormal or leaky blood vessels. Based in Mount Arlington, New Jersey, the company was founded in 2009 and is known for its lead compound, PAN-90806, a small-molecule selective VEGF receptor antagonist. This treatment shows potential for addressing conditions such as wet age-related macular degeneration and diabetic retinopathy, which can lead to significant vision loss. By seeking to license and develop new therapeutics, PanOptica aims to enhance the effectiveness of existing treatments and provide solutions for previously untreatable disorders, ultimately improving patients' vision and quality of life.
Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing therapeutics aimed at addressing significant unmet medical needs in cancer treatment, particularly those related to abnormal gene expression and drug resistance. The company's lead product candidates include CPI-0610, currently undergoing Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, which is in Phase Ib/II trials for metastatic castration-resistant prostate cancer alongside androgen receptor signaling inhibitors. Additionally, Constellation is developing CPI-0209, which is in the dose escalation phase of a Phase I/II clinical trial for solid tumors. Founded in 2008, the company was previously known as Epigenetix, Inc. and has established itself as a pioneer in the emerging field of epigenetics, which focuses on selective regulators of epigenetic function crucial for gene expression control.
Magenta is focused on improving the patient experience in transplant medicine, with the goal of bringing this lifesaving procedure to more patients. Over the past 50 years, stem cell transplantation has been used in more than 1M patients worldwide. It is currently the only treatment with the potential to cure some of the most devastating hematologic cancers and autoimmune diseases. Despite the increased use and clinical advancements over the past several decades, stem cell transplant remains a high-risk last-resort therapeutic option due to the toxicity and potential long-term side effects.
Tango Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cancer therapies utilizing the principle of synthetic lethality. Established in 2014, the company aims to discover novel drug targets that address driver genes in cancer. Its research is concentrated on three primary areas: counteracting the loss of tumor suppressor genes, reversing cancer cells' ability to evade the immune system, and identifying effective drug combinations that surpass the efficacy of single-agent therapies. By leveraging these strategies, Tango Therapeutics seeks to deliver next-generation targeted treatments for patients battling cancer.
Rhythm Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing peptide therapeutics for the treatment of rare genetic disorders, particularly those leading to life-threatening metabolic conditions. Its primary product candidate, setmelanotide, is a first-in-class melanocortin-4 receptor agonist currently undergoing Phase III clinical trials for obesity related to pro-opiomelanocortin and leptin receptor deficiencies, as well as Bardet-Biedl and Alström syndromes. Additionally, setmelanotide is in Phase II trials for various other genetic obesity disorders. The company is also advancing RM-853, an orally available ghrelin O-acyltransferase inhibitor, in preclinical development for Prader-Willi syndrome. Founded in 2008 and headquartered in Boston, Massachusetts, Rhythm Pharmaceuticals aims to address significant unmet medical needs in the realm of genetic metabolic disorders through innovative therapies.
Neon Therapeutics is a clinical-stage biopharmaceutical company specializing in neoantigen-targeted therapies aimed at advancing cancer treatment. By focusing on the immune system's response to neoantigens, the company seeks to develop innovative therapies that enhance the body's ability to fight cancer. Its product pipeline includes NEO-PV-01, NEO-PTC-01, and NEO-SV-01, which are designed to leverage the unique characteristics of neoantigens to improve patient outcomes.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.
Goldfinch Bio, Inc. is a clinical-stage biotechnology company dedicated to discovering and developing precision therapies for kidney diseases. The company focuses on researching and commercializing treatments for conditions such as focal segmental glomerulosclerosis, diabetic nephropathy, and polycystic kidney disease. Notable programs include GFB-887, a selective inhibitor of the TRPC5 channel, and GFB-024, a cannabinoid receptor 1 inverse agonist. Goldfinch Bio is also developing the Kidney Genome Atlas, a genomic registry aimed at identifying new disease targets and biomarkers, and utilizes a biology platform that leverages stem cell science to create human organoid models for target validation. Founded in 2016 and based in Cambridge, Massachusetts, Goldfinch Bio has established a strategic collaboration with Gilead Sciences to enhance its capabilities in kidney disease therapy development.
Magenta is focused on improving the patient experience in transplant medicine, with the goal of bringing this lifesaving procedure to more patients. Over the past 50 years, stem cell transplantation has been used in more than 1M patients worldwide. It is currently the only treatment with the potential to cure some of the most devastating hematologic cancers and autoimmune diseases. Despite the increased use and clinical advancements over the past several decades, stem cell transplant remains a high-risk last-resort therapeutic option due to the toxicity and potential long-term side effects.
Relay Therapeutics is a clinical-stage precision medicines company based in Cambridge, Massachusetts, focused on transforming the drug discovery process, particularly in targeted oncology. The company employs an innovative allosteric drug-discovery platform that integrates computational techniques with experimental methods to analyze protein motion and interactions. This approach aids in the development of therapies for complex diseases, including cancer. Relay's product candidates include RLY-1971, an oral small molecule inhibitor targeting SHP2, currently undergoing Phase 1 trials for advanced solid tumors; RLY-4008, a selective inhibitor of FGFR2 for tumors with specific oncogenic alterations; and RLY-PI3K1047, which targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. Founded in 2015, Relay Therapeutics is dedicated to enhancing small molecule therapeutic discovery through its advanced platform and targeted treatment strategies.
Element Science, Inc. is a medical device and digital health company focused on developing solutions for high-risk cardiovascular patients. The company's flagship product is a patch-based wearable cardioverter defibrillator that continuously monitors heart activity to protect against sudden cardiac death. This device integrates advanced data science and machine learning algorithms with strict electromechanical medical device standards, creating a proprietary digital platform that enhances patient care as individuals transition from hospital to home. Founded in 2011 and headquartered in San Francisco, California, Element Science aims to address critical health needs and reduce hospitalization rates associated with heart disease. The company was previously known as Revive Defibrillation Systems, Inc. before adopting its current name in 2014.
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for genetically defined diseases with high unmet medical needs. The company's lead product candidate, losmapimod, is a small molecule currently undergoing Phase 2b clinical trials for the treatment of facioscapulohumeral muscular dystrophy (FSHD), a progressive muscle-wasting disorder. Another key candidate, FTX-6058, aims to increase fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia. In addition to these programs, Fulcrum is exploring drug targets for other conditions such as Duchenne muscular dystrophy, Friedreich ataxia, myotonic dystrophy 1, and various neurological and pulmonary diseases. The company has established collaborations with Acceleron Pharma and MyoKardia to advance research and develop targeted therapies for pulmonary diseases and genetic cardiomyopathies, respectively. Founded in 2015, Fulcrum Therapeutics is committed to improving the lives of patients facing significant health challenges.
PanOptica, Inc. is a biopharmaceutical company focused on developing innovative topical eye drops for the treatment of sight-threatening eye diseases associated with abnormal or leaky blood vessels. Based in Mount Arlington, New Jersey, the company was founded in 2009 and is known for its lead compound, PAN-90806, a small-molecule selective VEGF receptor antagonist. This treatment shows potential for addressing conditions such as wet age-related macular degeneration and diabetic retinopathy, which can lead to significant vision loss. By seeking to license and develop new therapeutics, PanOptica aims to enhance the effectiveness of existing treatments and provide solutions for previously untreatable disorders, ultimately improving patients' vision and quality of life.
Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, specializing in the discovery and development of therapies for fibrotic diseases. The company's lead candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, currently being developed for idiopathic pulmonary fibrosis and primary sclerosing cholangitis. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both conditions and is undergoing Phase 2a trials for IPF, with plans for a Phase 2a trial in PSC. Pliant is also advancing PLN-1474, a small-molecule selective inhibitor of avß1, aimed at treating liver fibrosis associated with nonalcoholic steatohepatitis, which is in Phase 1 clinical trials and has a partnership with Novartis. In addition to these clinical efforts, Pliant has two preclinical programs targeting oncology and muscular dystrophies. Founded in 2015, Pliant Therapeutics is committed to addressing unmet medical needs in the field of fibrosis.
Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing therapeutics aimed at addressing significant unmet medical needs in cancer treatment, particularly those related to abnormal gene expression and drug resistance. The company's lead product candidates include CPI-0610, currently undergoing Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, which is in Phase Ib/II trials for metastatic castration-resistant prostate cancer alongside androgen receptor signaling inhibitors. Additionally, Constellation is developing CPI-0209, which is in the dose escalation phase of a Phase I/II clinical trial for solid tumors. Founded in 2008, the company was previously known as Epigenetix, Inc. and has established itself as a pioneer in the emerging field of epigenetics, which focuses on selective regulators of epigenetic function crucial for gene expression control.
Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing therapies aimed at protecting, repairing, and restoring hearing. The company focuses on a range of hearing disorders, including those related to cancer treatments, cystic fibrosis, noise exposure, age-related and genetic hearing loss, as well as tinnitus. It utilizes advanced techniques such as single-cell genomics, bioinformatics, and precision gene therapy technologies to enhance its understanding of inner ear pathology and to develop effective treatments. Decibel Therapeutics also offers expertise in drug delivery to the inner ear, imaging, and pharmacokinetic modeling, contributing to innovative therapeutic approaches for patients experiencing various forms of hearing loss. Founded in 2013 and based in Boston, Massachusetts, Decibel Therapeutics was previously known as Hearing, Inc. before rebranding in 2014.
Neon Therapeutics is a clinical-stage biopharmaceutical company specializing in neoantigen-targeted therapies aimed at advancing cancer treatment. By focusing on the immune system's response to neoantigens, the company seeks to develop innovative therapies that enhance the body's ability to fight cancer. Its product pipeline includes NEO-PV-01, NEO-PTC-01, and NEO-SV-01, which are designed to leverage the unique characteristics of neoantigens to improve patient outcomes.
Corvia Medical, Inc. is a medical device company specializing in the development of structural heart devices aimed at treating heart failure. The company's primary innovation is the InterAtrial Shunt Device (IASD), a transcatheter device designed to address diastolic heart failure (DHF), also referred to as heart failure with preserved ejection fraction (HFpEF). The IASD system works by creating a small opening between the left and right atria, which helps to lower elevated left atrial pressure, a main contributor to DHF symptoms. Founded in 2009 and based in Andover, Massachusetts, Corvia Medical was previously known as DC Devices Inc. and rebranded in June 2015. Through its innovative approach, the company aims to alleviate symptoms and enhance the quality of life for patients affected by heart failure.
Rhythm Metabolic
Series A in 2015
Rhythm Metabolic is the subsidiary of Rhythm Pharmaceuticals that develops setmelanotide (RM-493), a novel peptide MC4 agonist for the treatment of obesity caused by genetic deficiencies in the MC4 pathway. It was established in 2013 and is headquartered in Boston, Massachusetts.
Editas Medicine is a clinical-stage company focused on developing innovative genome editing therapeutics to address serious diseases at the genetic level. Established in 2013 and headquartered in Cambridge, Massachusetts, with an additional site in Boulder, Colorado, the company leverages its proprietary CRISPR/Cas9 technology to create precise and corrective molecular modifications. This approach utilizes a protein-RNA complex, which includes the Cas9 enzyme and a guide RNA, to target and repair specific DNA sequences. Editas Medicine aims to translate its advances in genome editing into transformative human therapies, supported by a robust portfolio of patents and intellectual property that underpins its foundational technologies.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.
CytomX Therapeutics is an early stage, privately-funded biotechnology company developing Probodiesâ„¢, proteolytically-activated antibodies. Probodies, by their ability to site-direct the activity of antibodies, will result in an improved therapeutic index for validated targets as well enable the drugging of targets with broad tissue expression. Their mission, alone and with the help of partners, is to provide patients with more effective and less toxic therapies for severe illnesses such as cancer and inflammatory diseases.
Allena Pharmaceuticals is developing and commercializing non-systemic protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrology and urologic conditions. Its proprietary technological approach enables the design, formulation, and delivery of non-absorbed and stable enzymes orally and in sufficient doses for activity in the GI tract.
It was founded in 2011 and headquartered in Newton, Massachusetts.
Blueprint Medicines Corporation is a biopharmaceutical company that specializes in developing small molecule kinase inhibitors aimed at treating cancers and rare diseases driven by genomic abnormalities. The company’s pipeline includes avapritinib, which targets systemic mastocytosis and gastrointestinal stromal tumors, and BLU-263, an oral KIT inhibitor for indolent systemic mastocytosis and other mast cell disorders. Additionally, fisogatinib is in Phase I trials for advanced hepatocellular carcinoma, while pralsetinib targets RET-altered non-small cell lung cancer and medullary thyroid carcinoma. Other investigational compounds include BLU-782, aimed at treating fibrodysplasia ossificans progressive. Established in 2008 and based in Cambridge, Massachusetts, Blueprint Medicines utilizes its proprietary chemical library and Insights-to-Validation Platform to develop personalized therapies that address specific molecular drivers of cancer and the challenges posed by resistance mechanisms. The company has formed collaboration agreements with several pharmaceutical entities to enhance its research and development efforts.
MyoKardia, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing targeted therapies for rare cardiovascular diseases, particularly heritable cardiomyopathies and genetically-driven heart failure. Founded in 2012 and headquartered in Brisbane, California, the company focuses on addressing biomechanical defects in cardiac muscle contraction. Its lead product candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin currently in Phase III clinical trials for hypertrophic cardiomyopathy (HCM). Additionally, MyoKardia is developing Danicamtiv, a small molecule that has completed Phase I and IIa trials for dilated cardiomyopathy. The company's preclinical pipeline includes programs targeting hypercontractility and impaired relaxation in HCM, as well as treatments for diastolic dysfunction. As of November 2020, MyoKardia operates as a subsidiary of Bristol-Myers Squibb Company.
Corvia Medical, Inc. is a medical device company specializing in the development of structural heart devices aimed at treating heart failure. The company's primary innovation is the InterAtrial Shunt Device (IASD), a transcatheter device designed to address diastolic heart failure (DHF), also referred to as heart failure with preserved ejection fraction (HFpEF). The IASD system works by creating a small opening between the left and right atria, which helps to lower elevated left atrial pressure, a main contributor to DHF symptoms. Founded in 2009 and based in Andover, Massachusetts, Corvia Medical was previously known as DC Devices Inc. and rebranded in June 2015. Through its innovative approach, the company aims to alleviate symptoms and enhance the quality of life for patients affected by heart failure.
Nurix Therapeutics is a biopharmaceutical company dedicated to the discovery and development of small molecule therapies aimed at treating cancer and immune disorders. The company focuses on innovative approaches to modulate cellular protein levels, utilizing its expertise in the ubiquitin-proteasome system. Its lead preclinical candidates include NX-2127, an orally available Bruton’s tyrosine kinase (BTK) degrader targeting relapsed or refractory B-cell malignancies, and NX-1607, a Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology applications. Nurix also offers DELigase, a discovery platform that identifies and advances novel drug candidates by targeting E3 ligases, which play a crucial role in protein regulation. Founded in 2009 and based in San Francisco, the company has established strategic collaborations with major pharmaceutical firms, enhancing its potential in the competitive biopharmaceutical landscape.
PanOptica, Inc. is a biopharmaceutical company focused on developing innovative topical eye drops for the treatment of sight-threatening eye diseases associated with abnormal or leaky blood vessels. Based in Mount Arlington, New Jersey, the company was founded in 2009 and is known for its lead compound, PAN-90806, a small-molecule selective VEGF receptor antagonist. This treatment shows potential for addressing conditions such as wet age-related macular degeneration and diabetic retinopathy, which can lead to significant vision loss. By seeking to license and develop new therapeutics, PanOptica aims to enhance the effectiveness of existing treatments and provide solutions for previously untreatable disorders, ultimately improving patients' vision and quality of life.
Element Science, Inc. is a medical device and digital health company focused on developing solutions for high-risk cardiovascular patients. The company's flagship product is a patch-based wearable cardioverter defibrillator that continuously monitors heart activity to protect against sudden cardiac death. This device integrates advanced data science and machine learning algorithms with strict electromechanical medical device standards, creating a proprietary digital platform that enhances patient care as individuals transition from hospital to home. Founded in 2011 and headquartered in San Francisco, California, Element Science aims to address critical health needs and reduce hospitalization rates associated with heart disease. The company was previously known as Revive Defibrillation Systems, Inc. before adopting its current name in 2014.
NinePoint Medical, Inc. is a medical device company based in Bedford, Massachusetts, that specializes in optical coherence tomography (OCT) imaging systems for assessing human tissue microstructure. The company's flagship product, the NvisionVLE Imaging System, provides real-time volumetric images of the esophagus and bile duct, enabling healthcare professionals across various specialties, including gastroenterology and pulmonology, to conduct advanced imaging procedures. This technology allows for high-resolution, cross-sectional views that facilitate accurate diagnoses and effective therapies during medical procedures. NinePoint aims to enhance the efficiency of patient care by integrating access to imaging, diagnosis, and treatment in a single procedure, ultimately improving patient outcomes and reducing healthcare costs. The company markets its products through distributors both domestically and internationally. Established in 2008, NinePoint Medical was formerly known as Convergence Devices, Inc. and underwent a name change in 2009.
SAGE Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative treatments for central nervous system (CNS) disorders. Its lead product, ZULRESSO, is an intravenous formulation of brexanolone designed for postpartum depression. The company's pipeline includes SAGE-217, a neuroactive steroid in Phase III trials for various depressive disorders and anxiety, and SAGE-324, currently in Phase II trials for essential tremors and previously tested for other neurological conditions. Additionally, SAGE-718, which targets multiple CNS disorders, has completed Phase I trials, while SAGE-904 and SAGE-689 are in early clinical stages for NMDA-related disorders. SAGE Therapeutics has formed strategic collaborations with Shionogi & Co., Ltd. and Biogen Inc. for the development and commercialization of its key product candidates. Founded in 2010 and headquartered in Cambridge, Massachusetts, the company aims to address the unmet needs of patients affected by debilitating CNS disorders through scientific innovation and strategic partnerships.
Voyager Therapeutics is a clinical-stage gene therapy company based in Cambridge, Massachusetts, focused on developing innovative treatments for severe neurological diseases. The company's lead candidate, VY-AADC, is currently undergoing an open-label Phase 1b clinical trial for Parkinson's disease. In addition to this, Voyager's preclinical pipeline includes therapies targeting amyotrophic lateral sclerosis, Huntington's disease, Friedreich's ataxia, and various tauopathies and synucleinopathies, which encompass conditions like Alzheimer's disease and Lewy Body Dementia. Voyager Therapeutics emphasizes advancing adeno-associated virus (AAV) gene therapy through innovations in vector optimization, dosing techniques, and production processes. The company has established strategic collaborations with the University of Massachusetts and ClearPoint Neuro, along with partnerships with Brammer Bio and Fujifilm Diosynth Biotechnologies to enhance its gene therapy programs. Furthermore, Voyager has a collaboration agreement with Neurocrine Biosciences for the research, development, and commercialization of AAV-based gene therapies. Founded in 2013, Voyager Therapeutics is committed to addressing critical unmet medical needs in the field of central nervous system disorders.
Igenica, Inc. is a biotherapeutic company based in Burlingame, California, specializing in the discovery and development of antibodies and antibody-drug conjugates for cancer treatment. The company is dedicated to advancing immunotherapies and functional antibodies that target tumors, as well as creating antibody-drug conjugates. Igenica's key products include IGN523, a humanized monoclonal antibody aimed at various hematologic and solid tumors; IGN786, an antibody-drug conjugate; and IGN381, which targets immune checkpoints in the tumor microenvironment. Founded in 2008, Igenica operates with a strategic oncology research agreement with MedImmune and is backed by prominent life science investors. The leadership team at Igenica has significant experience in antibody drug discovery and has contributed to the development of multiple approved antibody therapeutic products.
Blueprint Medicines Corporation is a biopharmaceutical company that specializes in developing small molecule kinase inhibitors aimed at treating cancers and rare diseases driven by genomic abnormalities. The company’s pipeline includes avapritinib, which targets systemic mastocytosis and gastrointestinal stromal tumors, and BLU-263, an oral KIT inhibitor for indolent systemic mastocytosis and other mast cell disorders. Additionally, fisogatinib is in Phase I trials for advanced hepatocellular carcinoma, while pralsetinib targets RET-altered non-small cell lung cancer and medullary thyroid carcinoma. Other investigational compounds include BLU-782, aimed at treating fibrodysplasia ossificans progressive. Established in 2008 and based in Cambridge, Massachusetts, Blueprint Medicines utilizes its proprietary chemical library and Insights-to-Validation Platform to develop personalized therapies that address specific molecular drivers of cancer and the challenges posed by resistance mechanisms. The company has formed collaboration agreements with several pharmaceutical entities to enhance its research and development efforts.
Soffio Medical is a medical company that develops medical apparatus for respiratory diseases.
The company is based in Boston, Massachusetts.
Editas Medicine is a clinical-stage company focused on developing innovative genome editing therapeutics to address serious diseases at the genetic level. Established in 2013 and headquartered in Cambridge, Massachusetts, with an additional site in Boulder, Colorado, the company leverages its proprietary CRISPR/Cas9 technology to create precise and corrective molecular modifications. This approach utilizes a protein-RNA complex, which includes the Cas9 enzyme and a guide RNA, to target and repair specific DNA sequences. Editas Medicine aims to translate its advances in genome editing into transformative human therapies, supported by a robust portfolio of patents and intellectual property that underpins its foundational technologies.
SAGE Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative treatments for central nervous system (CNS) disorders. Its lead product, ZULRESSO, is an intravenous formulation of brexanolone designed for postpartum depression. The company's pipeline includes SAGE-217, a neuroactive steroid in Phase III trials for various depressive disorders and anxiety, and SAGE-324, currently in Phase II trials for essential tremors and previously tested for other neurological conditions. Additionally, SAGE-718, which targets multiple CNS disorders, has completed Phase I trials, while SAGE-904 and SAGE-689 are in early clinical stages for NMDA-related disorders. SAGE Therapeutics has formed strategic collaborations with Shionogi & Co., Ltd. and Biogen Inc. for the development and commercialization of its key product candidates. Founded in 2010 and headquartered in Cambridge, Massachusetts, the company aims to address the unmet needs of patients affected by debilitating CNS disorders through scientific innovation and strategic partnerships.
Edimer Pharmaceuticals: Working toward improving the health and quality of life of families living with XLHED. Edimer Pharmaceuticals is dedicated to developing EDI200 as a treatment for X-linked Hypohydrotic Ectodermal Dysplasia (XLHED). XLHED is a rare, orphan disease that causes a range of symptoms including lack of sweat glands, poor temperature control, respiratory problems, and hair and tooth malformations. Edimer is led by a team of seasoned biotechnology industry veterans with deep experience in drug development complemented by a strong network of world-class clinical and scientific advisers.
Alcresta Therapeutics, Inc. develops and commercializes enzyme-based products aimed at treating gastrointestinal disorders and rare diseases. The company's primary offering, RELiZORB, is a digestive enzyme cartridge designed to replicate the function of pancreatic lipase for adults on enteral tube feeding who struggle to break down and absorb fats. Established in 2011 and based in Warren, New Jersey, Alcresta focuses on innovative, point-of-care nutritional products that enhance nutrition and manage health conditions for various populations, including infants, aging adults, and individuals with acute or chronic diseases. The company leverages its expertise in both adult and pediatric nutrition, along with protein manufacturing and regulatory knowledge, to address the unmet nutritional needs of those with compromised health.
Afferent Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It develops medicines to treat chronic pain by targeting P2X3 receptors in nerve fibers. The company’s AF-219, a compound that completed two Phase 1 clinical studies. Afferent Pharmaceuticals, Inc. was founded in 2009 and is based in San Mateo, California.
Nurix Therapeutics is a biopharmaceutical company dedicated to the discovery and development of small molecule therapies aimed at treating cancer and immune disorders. The company focuses on innovative approaches to modulate cellular protein levels, utilizing its expertise in the ubiquitin-proteasome system. Its lead preclinical candidates include NX-2127, an orally available Bruton’s tyrosine kinase (BTK) degrader targeting relapsed or refractory B-cell malignancies, and NX-1607, a Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology applications. Nurix also offers DELigase, a discovery platform that identifies and advances novel drug candidates by targeting E3 ligases, which play a crucial role in protein regulation. Founded in 2009 and based in San Francisco, the company has established strategic collaborations with major pharmaceutical firms, enhancing its potential in the competitive biopharmaceutical landscape.
TARIS BioMedical, Inc., a therapeutically urology company, develops treatments for patients suffering from difficult-to-treat bladder diseases. It develops therapies for debilitating conditions, including bladder cancer and overactive bladder. The company was founded in 2008 and is based in Lexington, Massachusetts. As of December 20, 2019, TARIS BioMedical, Inc. operates as a subsidiary of Janssen Research & Development, LLC.
Corvia Medical, Inc. is a medical device company specializing in the development of structural heart devices aimed at treating heart failure. The company's primary innovation is the InterAtrial Shunt Device (IASD), a transcatheter device designed to address diastolic heart failure (DHF), also referred to as heart failure with preserved ejection fraction (HFpEF). The IASD system works by creating a small opening between the left and right atria, which helps to lower elevated left atrial pressure, a main contributor to DHF symptoms. Founded in 2009 and based in Andover, Massachusetts, Corvia Medical was previously known as DC Devices Inc. and rebranded in June 2015. Through its innovative approach, the company aims to alleviate symptoms and enhance the quality of life for patients affected by heart failure.
Jounce Therapeutics is a clinical-stage immunotherapy company focused on developing innovative cancer treatments that harness the immune system to target and eliminate cancer cells. The company's lead product, vopratelimab, is a monoclonal antibody currently in Phase II trials for patients with non-small cell lung cancer and urothelial cancer, particularly those who have not responded to PD-1/PD-L1 inhibitors. Additionally, Jounce is advancing several other therapeutic candidates, including JTX-4014, an anti-PD-1 antibody intended for combination therapy, and JTX-1811, which aims to selectively deplete T regulatory cells in the tumor microenvironment. The company also develops JTX-8064, an antibody targeting a receptor on macrophages. Founded in 2013 by experts in immunobiology and cancer research, Jounce Therapeutics is headquartered in Cambridge, Massachusetts, and is committed to improving patient outcomes through its proprietary immunotherapy platform.
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
Motus Therapeutics is a biotechnology company developing peptide therapeutics that address unmet needs in metabolic diseases. Rhythm investors include MPM Capital and New Enterprise Associates. The company is based in Boston, Massachusetts.
Cibiem is a medical device company leveraging its proprietary, minimally invasive, catheter-based approach focused on Carotid Body Modulation (CBM) for the treatment of sympathetic nervous system-mediated diseases such as hypertension, heart failure, diabetes and renal failure. The company was co-founded by Mark Gelfand and Howard R. Levin, M.D., the proven team of innovators and entrepreneurs behind Coridea. The company is backed by top-tier venture investors Third Rock Ventures and SV Life Sciences.
MyoKardia, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing targeted therapies for rare cardiovascular diseases, particularly heritable cardiomyopathies and genetically-driven heart failure. Founded in 2012 and headquartered in Brisbane, California, the company focuses on addressing biomechanical defects in cardiac muscle contraction. Its lead product candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin currently in Phase III clinical trials for hypertrophic cardiomyopathy (HCM). Additionally, MyoKardia is developing Danicamtiv, a small molecule that has completed Phase I and IIa trials for dilated cardiomyopathy. The company's preclinical pipeline includes programs targeting hypercontractility and impaired relaxation in HCM, as well as treatments for diastolic dysfunction. As of November 2020, MyoKardia operates as a subsidiary of Bristol-Myers Squibb Company.
Foundation Medicine, Inc. specializes in providing molecular information products aimed at enhancing cancer treatment through genomic insights. The company utilizes proprietary methods and algorithms to analyze cancer specimens, helping physicians tailor treatments based on the unique genetic profile of each patient's tumor. Its product offerings include FoundationOne for solid tumors, FoundationOne Heme for hematologic malignancies, and various diagnostic assays such as FoundationFocus CDxBRCA for ovarian cancer. Additionally, Foundation Medicine develops a knowledgebase called FoundationCORE to disseminate scientific advancements within the oncology community. The company collaborates with major pharmaceutical firms and research organizations to advance precision medicine and develop companion diagnostics. Founded in 2009 and headquartered in Cambridge, Massachusetts, Foundation Medicine operates as a subsidiary of Roche Holdings, Inc. It aims to transform cancer care by enabling personalized treatment strategies informed by detailed genomic profiling.
CytomX Therapeutics is an early stage, privately-funded biotechnology company developing Probodiesâ„¢, proteolytically-activated antibodies. Probodies, by their ability to site-direct the activity of antibodies, will result in an improved therapeutic index for validated targets as well enable the drugging of targets with broad tissue expression. Their mission, alone and with the help of partners, is to provide patients with more effective and less toxic therapies for severe illnesses such as cancer and inflammatory diseases.
Bluebird Bio is a clinical-stage biotechnology company focused on developing transformative gene therapies for severe genetic diseases and cancer. The company is engaged in researching and commercializing therapies that aim to genetically modify patients' cells to correct the underlying genetic causes of diseases. Key programs include LentiGlobin for β-thalassemia and sickle cell disease, and Lenti-D for cerebral adrenoleukodystrophy. In oncology, bluebird bio is developing CAR T cell therapies, such as bb2121 and bb21217, for multiple myeloma. The company has formed strategic collaborations with Bristol-Myers Squibb and Regeneron Pharmaceuticals to advance gene therapies in oncology, and works with various partners to develop innovative solutions in cancer treatment and in vivo genome editing for genetic disorders. Founded in 1992 and headquartered in Cambridge, Massachusetts, bluebird bio generates revenue through collaboration arrangements, research fees, license fees, and grants.
GBT is a clinical-stage biopharmaceutical company that focuses on discovering, developing, and delivering innovative treatments that provide hope to underserved patient communities. GBT is developing its product candidate, voxelotor, as an oral, once-daily therapy for sickle cell disease.
It was founded in 2012 and headquartered in San Francisco, California.
Motus Therapeutics is a biotechnology company developing peptide therapeutics that address unmet needs in metabolic diseases. Rhythm investors include MPM Capital and New Enterprise Associates. The company is based in Boston, Massachusetts.
Igenica, Inc. is a biotherapeutic company based in Burlingame, California, specializing in the discovery and development of antibodies and antibody-drug conjugates for cancer treatment. The company is dedicated to advancing immunotherapies and functional antibodies that target tumors, as well as creating antibody-drug conjugates. Igenica's key products include IGN523, a humanized monoclonal antibody aimed at various hematologic and solid tumors; IGN786, an antibody-drug conjugate; and IGN381, which targets immune checkpoints in the tumor microenvironment. Founded in 2008, Igenica operates with a strategic oncology research agreement with MedImmune and is backed by prominent life science investors. The leadership team at Igenica has significant experience in antibody drug discovery and has contributed to the development of multiple approved antibody therapeutic products.
Nurix Therapeutics is a biopharmaceutical company dedicated to the discovery and development of small molecule therapies aimed at treating cancer and immune disorders. The company focuses on innovative approaches to modulate cellular protein levels, utilizing its expertise in the ubiquitin-proteasome system. Its lead preclinical candidates include NX-2127, an orally available Bruton’s tyrosine kinase (BTK) degrader targeting relapsed or refractory B-cell malignancies, and NX-1607, a Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology applications. Nurix also offers DELigase, a discovery platform that identifies and advances novel drug candidates by targeting E3 ligases, which play a crucial role in protein regulation. Founded in 2009 and based in San Francisco, the company has established strategic collaborations with major pharmaceutical firms, enhancing its potential in the competitive biopharmaceutical landscape.
Sesen Bio, Inc. is a late-stage clinical company focused on developing targeted fusion protein therapeutics for cancer treatment. Its lead product, Vicinium, is a locally-administered therapy currently undergoing phase 3 trials for high-risk non-muscle invasive bladder cancer (NMIBC). Vicinium is designed as a fusion protein that combines an anti-epithelial cell adhesion molecule antibody fragment with a cytotoxic protein to target cancer cells effectively. Additionally, Sesen Bio is exploring the use of Vicinium in combination with Durvalumab and other checkpoint inhibitors for various cancer indications, including squamous cell carcinoma of the head and neck. The company is also collaborating with Leiden University Medical Center on the co-development of an imaging agent. Founded in 2008 and headquartered in Cambridge, Massachusetts, Sesen Bio was previously known as Eleven Biotherapeutics before rebranding in May 2018.
Alcresta Therapeutics, Inc. develops and commercializes enzyme-based products aimed at treating gastrointestinal disorders and rare diseases. The company's primary offering, RELiZORB, is a digestive enzyme cartridge designed to replicate the function of pancreatic lipase for adults on enteral tube feeding who struggle to break down and absorb fats. Established in 2011 and based in Warren, New Jersey, Alcresta focuses on innovative, point-of-care nutritional products that enhance nutrition and manage health conditions for various populations, including infants, aging adults, and individuals with acute or chronic diseases. The company leverages its expertise in both adult and pediatric nutrition, along with protein manufacturing and regulatory knowledge, to address the unmet nutritional needs of those with compromised health.
Private Equity Round in 2012
Warp Drive Bio, LLC develops genomic technology to discover drugs of natural origin. The company also engages in the development of drugs. Warp Drive Bio, LLC was incorporated in 2010 and is based in Cambridge, Massachusetts. As of October 24, 2018, Warp Drive Bio, LLC operates as a subsidiary of REVOLUTION Medicines, Inc.
Ember Therapeutics is a product-focused company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease. Today’s
rising epidemic of obesity and Type 2 diabetes coupled with the lack of innovation in the industry’s metabolic disorder treatment pipeline underscores the need for novel, peripherallyacting treatments with improved safety profiles. Ember’s unique approach leverages recent research breakthroughs in brown fat biology to develop a pipeline of proprietary large and small molecules designed to amplify the body’s innate ability to efficiently burn fuels like glucose.
Ember’s expertise is also driving the development of the next generation of highly selective insulin sensitizers that have robust anti-diabetic effects, but lack the serious side effects of
currently approved insulin sensitizers. Formerly known as Adipothermics, Ember Therapeutics is a private company launched in 2011 by renowned scientific founders, an experienced leadership team and Third Rock Ventures.
Agios Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of therapies targeting cellular metabolism, particularly in cancer and rare genetic disorders. The company offers TIBSOVO, an oral targeted inhibitor approved for treating relapsed or refractory acute myeloid leukemia (AML) and newly diagnosed AML, as well as IDHIFA, which targets AML patients with specific genetic mutations. Agios is advancing multiple clinical programs, including TIBSOVO for frontline AML and cholangiocarcinoma, and developing mitapivat for pyruvate kinase deficiency and thalassemia. Other investigational compounds include vorasidenib for solid tumors and AG-270 for specific cancer types. Agios employs a precision medicine approach, focusing on genetically or biomarker-defined patient populations to enhance the potential for successful early clinical proof of concept and accelerated approvals. The company was originally established in 2007 under the name Cancer Metabolism Therapeutics before rebranding to Agios Pharmaceuticals in 2008.
Allena Pharmaceuticals is developing and commercializing non-systemic protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrology and urologic conditions. Its proprietary technological approach enables the design, formulation, and delivery of non-absorbed and stable enzymes orally and in sufficient doses for activity in the GI tract.
It was founded in 2011 and headquartered in Newton, Massachusetts.
Foundation Medicine, Inc. specializes in providing molecular information products aimed at enhancing cancer treatment through genomic insights. The company utilizes proprietary methods and algorithms to analyze cancer specimens, helping physicians tailor treatments based on the unique genetic profile of each patient's tumor. Its product offerings include FoundationOne for solid tumors, FoundationOne Heme for hematologic malignancies, and various diagnostic assays such as FoundationFocus CDxBRCA for ovarian cancer. Additionally, Foundation Medicine develops a knowledgebase called FoundationCORE to disseminate scientific advancements within the oncology community. The company collaborates with major pharmaceutical firms and research organizations to advance precision medicine and develop companion diagnostics. Founded in 2009 and headquartered in Cambridge, Massachusetts, Foundation Medicine operates as a subsidiary of Roche Holdings, Inc. It aims to transform cancer care by enabling personalized treatment strategies informed by detailed genomic profiling.